Enhanced metabolism & decrease serum conc by rifampicin, rifabutin & rifamycin derivatives. Diminished efficacy by oxcarbazepine, carbamazepine, eslicabazepin, clobazam, perampanel, primidone, topiramate, rufinamid, felbamate, phenytoin, phosphenytoin. Decreased serum conc by antiretroviral drugs eg, PIs (eg, lopinavir) & NNRTIs (eg, nevirapine); bile acid sequestrant, colesevelam, prucalopride, sugammadex, lumacaftor, mifepriston, ulipristal, mycophenolate, lesinurad. Increased serum conc by atazanavir, cobicistat, boceprevir, tripranavir; griseofulvin. Reduced efficacy by some antidiabetics, retionoid, antiemetic, antimalarial, anticancer drugs. Inhibited metabolism by 5α-reductase inhibitors eg, finasteride & dutasteride. Altered circulating levels by St John's wort, bosentan, deferasirox, mitotane, sarilumab, siltuximab and tocilizumab. Reduced plasma conc of lamotrigine. Diminished therapeutic efficacy of anticoagulants, antidiabetics. Enhance thrombogenic effect of C1 inhibitors, tranexamic acid, thalidomide & pomalidomide. Increase serum conc of voriconazole. Enhance hepatotoxic effect of cyclosporine. Increase the risk of ALT elevations w/ ombitasvir-/paritaprevir-/ritonavir-/dasubuvir-/ glecaprevir-/pibrentasvir-containing medicinal products. Interference w/ lab tests results.